bosentan anhydrous has been researched along with Cardiac Hypertrophy in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (25.00) | 18.2507 |
2000's | 6 (50.00) | 29.6817 |
2010's | 2 (16.67) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Chen, Z; Deng, X; Li, W; Peng, Y; Wang, Y; Xiao, Y; Xiao, Z; Zeng, Y | 1 |
Hoepf, TM; Holycross, BJ; McCune, SA; Radin, MJ | 1 |
Janda, S; Quon, BS; Swiston, J | 1 |
Cordaillat, M; Gaillard, V; Jover, B; Lartaud, I; Reboul, C; Rugale, C | 1 |
Capuano, V; Coulombe, A; Deroubaix, E; Ferron, L; Renaud, JF; Ruchon, Y | 1 |
Bäcker, A; Cervenka, L; Kramer, HJ; Opocensky, M; Vanêcková, I; Vernerová, Z | 1 |
Bäcker, A; Cervenka, L; Dvorák, P; Eis, V; Kramer, HJ; Opocenský, M; Schejbalová, S; Vanecková, I; Vernerová, Z | 1 |
Li, JS; Schiffrin, EL | 1 |
Clozel, JP; Clozel, M; Gonzales, MF; Hess, P; Heudes, D; Karam, H; Löffler, BM | 1 |
Bruneval, P; Clozel, JP; Clozel, M; Gonzales, MF; Heudes, D; Karam, H; Löffler, BM | 1 |
Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W | 1 |
Belabbas, H; Herizi, A; Jover, B; Mimran, A | 1 |
1 review(s) available for bosentan anhydrous and Cardiac Hypertrophy
Article | Year |
---|---|
HIV and pulmonary arterial hypertension: a systematic review.
Topics: Adolescent; Adult; Antihypertensive Agents; Antiretroviral Therapy, Highly Active; Bosentan; Cardiomegaly; CD4 Lymphocyte Count; Child; Cohort Studies; Confounding Factors, Epidemiologic; Databases, Bibliographic; Diagnosis, Differential; Drug Therapy, Combination; Dyspnea; Echocardiography; Electrocardiography; Epoprostenol; Female; Hemodynamics; HIV Infections; Humans; Hypertension, Pulmonary; Male; Prevalence; Radiography; Reverse Transcriptase Inhibitors; Sulfonamides; Survival Rate; Treatment Outcome | 2010 |
11 other study(ies) available for bosentan anhydrous and Cardiac Hypertrophy
Article | Year |
---|---|
Ligation of patent ductus venosus in a child with pulmonary arterial hypertension and hypersplenism: A case report.
Topics: Aftercare; Antihypertensive Agents; Bosentan; Cardiomegaly; Child, Preschool; Combined Modality Therapy; Echocardiography; Humans; Hypersplenism; Ligation; Male; Portal Vein; Pulmonary Arterial Hypertension; Radiography, Thoracic; Tadalafil; Tomography, X-Ray Computed; Treatment Outcome; Vascular Malformations; Vascular Resistance; Vasodilator Agents | 2020 |
Salt-induced cardiac hypertrophy is independent of blood pressure and endothelin in obese, heart failure-prone SHHF rats.
Topics: Animals; Base Sequence; Blood Pressure; Bosentan; Cardiomegaly; DNA Primers; Endothelin Receptor Antagonists; Endothelins; Gene Expression; Heart Failure; Leptin; Male; Nitric Oxide Synthase; Obesity; Rats; RNA, Messenger; Sodium Chloride, Dietary; Sulfonamides | 2008 |
Plasma volume and arterial stiffness in the cardiac alterations associated with long-term high sodium feeding in rats.
Topics: Animals; Aorta, Thoracic; Blood Flow Velocity; Bosentan; Cardiomegaly; Echocardiography, Doppler; Endothelin Receptor Antagonists; Endothelin-1; Male; Plasma Volume; Pulsatile Flow; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Sulfonamides; Vascular Resistance | 2011 |
Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Bosentan; Butadienes; Calcium Channels, T-Type; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegaly; Constriction, Pathologic; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; Flavonoids; Gene Expression; Losartan; Male; Membrane Potentials; Mitogen-Activated Protein Kinase Kinases; Myocytes, Cardiac; Nickel; Nitriles; Oligopeptides; Peptides, Cyclic; Piperidines; Rats; Rats, Wistar; Receptors, Angiotensin; Receptors, Endothelin; RNA, Messenger; Signal Transduction; Sulfonamides | 2003 |
Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Endothelin A Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heart Ventricles; Hypertension; Kidney; Male; Myocardium; Organ Size; Osmolar Concentration; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Renin; Sodium Chloride, Dietary; Sulfonamides; Survival Analysis | 2005 |
Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Hypertension; Male; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2006 |
Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist.
Topics: Administration, Oral; Angiotensin II; Animals; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Endothelin Receptor Antagonists; Endothelins; Muscle, Smooth, Vascular; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sulfonamides | 1995 |
Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Bosentan; Calcium Channel Blockers; Cardiomegaly; Collagen; Coronary Circulation; Desoxycorticosterone; Enalapril; Endothelin Receptor Antagonists; Fibrosis; Hypertension; Male; Mibefradil; Myocardium; Perfusion; Rats; Rats, Wistar; Sulfonamides; Tetrahydronaphthalenes | 1996 |
Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Benzimidazoles; Body Weight; Bosentan; Calcium Channel Blockers; Cardiomegaly; Coronary Circulation; Enalapril; Endothelins; Fibrosis; Heart Ventricles; Hemodynamics; Hormones; Hypertension; Kidney; Mibefradil; Myocardium; Rats; Rats, Inbred SHR; Sulfonamides; Tetrahydronaphthalenes | 1996 |
Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Pressure; Bosentan; Cardiomegaly; Fibronectins; Heart; Humans; Hydralazine; Immunohistochemistry; Inflammation; Intercellular Adhesion Molecule-1; Kidney; Macrophages; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Renin; Sulfonamides; Thromboplastin; Transcription Factor AP-1; Vascular Cell Adhesion Molecule-1 | 2000 |
[Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan].
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Carotid Arteries; Endothelin Receptor Antagonists; Endothelins; Follow-Up Studies; Hypertension; Hypertrophy; Losartan; Male; Organ Size; Rats; Rats, Sprague-Dawley; Sulfonamides | 2000 |